2015 American Transplant Congress
DSA MFI Does Not Predict Late Antibody-Mediated Rejection Lesions Or Gene Expression Changes in Kidney Transplants
BACKGROUND: It is unclear whether donor-specific HLA antibody (DSA) levels at the time of a clinically-indicated biopsy can be predictive of the degree of antibody-mediated…2015 American Transplant Congress
Combination of Non-HLA and HLA-DSA Antibodies Identifies Liver Transplants Recipients With Highest Risk for Fibrosis Progression and Mortality
Recent data has shown an increased risk of fibrosis progression in HCV viremic liver transplant (LT) recipients with HLA DSA in serum. However, the role…2015 American Transplant Congress
DSA Detected by ELISA-PRA Is Associated With High Risk for Development of AMR in Stable Kidney Transplant Recipients
Background: Donor specific anti-HLA antibodies (DSA) are a major cause of antibody mediated rejection (AMR) and allograft loss, determining how to monitor patients for DSA…2015 American Transplant Congress
Desensitization Protocol Including Concomitant Bortezomib and Rituximab Did Not Reduce Calculated PRA Nor Mean MFI Values Among Waitlisted Patients for Deceased Donor Kidney Transplantation
Highly sensitized (HS) patients (pts) seldom have chance to receive deceased donor kidney transplant (DDKT). A desensitization (DES) program including bortezomib was employed to facilitate…2015 American Transplant Congress
De Novo DSA Would Not Necessarily Cause Graft Rejection After Renal Transplantation: Characteristics of DSA Developing Biopsy-Proven Chronic Antibody-Mediated Rejection
Kidney Center, Nagoya Daini Red Cross Hospital, Nagoya, Japan.
Introduction:De novo donor-specific HLA antibodies (dn DSA) production after renal transplantation has been reported to be associated with chronic antibody mediated rejection (CAMR), which leads…2015 American Transplant Congress
The Higher MFI of De Novo Donor-Specific Anti-HLA Antibodies Is Correlated With Graft Fibrosis Progression in Living Donor Liver Transplantation
Background. It has been shown that the development of de novo donor-specific anti-HLA antibodies (DSA) is associated with poorer graft outcome in kidney transplantation. However…2015 American Transplant Congress
The Effect of Preformed and De Novo Donor-Specific Antibodies (DSA) in Acute Rejection (AR) After Liver Transplantation (LTX)
BACKGROUND: The role of preformed and den novo formed DSA in LTX is not fully revealed. The aim of our study was to determine if…2015 American Transplant Congress
Interference of Therapeutic Antibodies Used in Desensitization Protocols On Lymphocytotoxicity Crossmatch Results
Background: Therapeutic antibodies used to desensitize patients awaiting a human leukocyte antigen (HLA) or ABO-mismatched graft are suspected to interfere with the lymphocytotoxicity crossmatch (LCT-XM)…2015 American Transplant Congress
Part II: Rates and Determinants of Progression for De Novo Donor-Specific Antibody Mediated Kidney Allograft Injury
The development of de novo donor-specific antibody (dnDSA) is an independent predictor of allograft loss in renal transplantation. Rates and determinants of clinical pathologic progression…2015 American Transplant Congress
Antibody Response Following Influenza Vaccination in Renal Transplant Recipients
Indiana University School of Medicne-IU Health, Indianapolis, IN.
Purpose: Following the recommended consensus guidelines of ATC for vaccination, at our institution we recommend annual vaccination for influenza + H1N1 (Flu) for renal transplant…
American Transplant Congress abstracts